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The 26 S proteasome is a large proteolytic machine, which
degrades most intracellular proteins. We found that thiore-
doxin,Txnl1/TRP32, binds toRpn11, a subunit of the regulatory
complexof thehuman26Sproteasome.Txnl1 is abundant,met-
abolically stable, andwidely expressed and is present in the cyto-
plasm and nucleus. Txnl1 has thioredoxin activity with a redox
potential of about250 mV. Mutant Txnl1 with one active site
cysteine replaced by serine formed disulfide bonds to eEF1A1, a
substrate-recruiting factor of the 26 S proteasome. eEF1A1 is
therefore a likely physiological substrate. In response to knock-
down of Txnl1, ubiquitin-protein conjugates were moderately
stabilized. Hence, Txnl1 is the first example of a direct connec-
tion between protein reduction and proteolysis, two major
intracellular protein quality control mechanisms.
Degradation of proteins in eukaryotic cells plays a pivotal
role in the regulation of several important processes, including
cell division, antigen presentation, and signal transduction (1).
Most intracellular proteins are degraded by the 26 S protea-
some, a 2.5-MDa protease complex composed of more than 30
different subunits (2).
To becomedegraded, proteins are typically first conjugated to a
chain of ubiquitinmoieties. This reaction is catalyzed by ubiquitin
ligases. The ubiquitin chains lend the proteins affinity for the 26 S
proteasome (3). For efficient degradation, certain ubiquitylated
proteins are shuttled to the 26 S proteasome by substrate recruit-
ing factors, such as Rad23, Dsk2, and eEF1A (4, 5).
The 26 S proteasome is composed of two stable subcom-
plexes, the proteolytically active 20 S core and 19 S regulatory
complexes, which bind to one or both ends of the cylindrical 20
S core particle (6). The regulatory complexes first recognize the
ubiquitylated substrates (3), before the substrates are deubiqui-
tylated (7, 8), unfolded (9, 10), and translocated into the 20 S
particle for degradation.
Although the 26 S proteasomehas been known formore than
20 years (11), novel subunits and cofactors have been described
recently (12, 13). Here we report another novel proteasome-
associated protein, Txnl1 (thioredoxin-like protein 1), that
associates directly with the proteasome subunit Rpn11.
Txnl1 exhibits thioredoxin activity and targets eEF1A1 in
vivo. Previous reports have shown that eEF1A1 transfers
misfolded nascent proteins from the ribosome to the 26 S
proteasome for degradation (5, 14, 15). Accordingly, ubiq-
uitin-protein conjugates were stabilized upon knockdown of
Txnl1 expression. Txnl1 therefore directly links protein
reduction and proteolysis, two major intracellular protein
quality control mechanisms.
EXPERIMENTAL PROCEDURES
Buffers—The buffers were as follows: buffer A, 25 mM Tris/
HCl, pH 7.6, 5 mM MgCl2, 5 mM ATP, 50 mM NaCl, 2 mM KCl,
2 mM DTT,2 10% glycerol; buffer B, 50 mM Tris/HCl, pH 8.0,
100 mM NaCl, 2 mM EDTA, 10% glycerol, 1 mM phenylmethyl-
sulfonyl fluoride, and Complete EDTA-free protease inhibitor
tablets (Roche Applied Science); buffer C, 50 mM Tris/HCl, pH
8.0, and 200 mM NaCl; buffer D, 100 mM NaH2PO4, 10 mM
Tris/HCl, and 8 M urea, pH 8.0; PBS, 133mMNaCl, 2.7mMKCl,
6.5 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4.
Plasmids and Proteins—Full-length cDNA encoding human
Txnl1 (Dr. Giannis Spyrou) was transferred to the appropriate
Gateway destination vectors (Invitrogen). PCR mutagenesis
was performedusingQuikChange (Stratagene). The expression
constructs for human Rpn11 and Csn5 were provided by Dr.
Wolfgang Dubiel. The proteins were expressed in BL21*(DE3)
(Invitrogen) and purified by standard methods.
Cell Culture—MelJuSo cells, stably transfected to express
CD3-yellow fluorescent protein (Dr. Nico P. Dantuma), HeLa
cells, and HEK293 cells were maintained at 37 °C in Dulbecco’s
modified Eagle’sminimal essentialmedium supplementedwith
10% newborn calf serum (Invitrogen) in a humidified atmo-
sphere with 5% CO2.
Electrophoresis and Blotting—Proteins were separated on
12.5% acrylamide gels with SDS or in nondenaturing 5% acryl-
amide gels (16). Proteins were transferred to BA83 (Schleicher
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tion (to R. H.-P.).
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&Schuell) nitrocellulosemembranes and probedwith antibod-
ies as indicated. For quantitative blotting, the blots were devel-
oped using alkaline phosphatase-coupled secondary antibod-
ies, and the color intensities were determined using UnScanIt
version 6.1 (Silk Scientific).
Antibodies—His6-tagged Txnl1 protein was used for genera-
tion of monoclonal antibodies essentially as described (17).
Monoclonal antibodies to proteasome subunits were from
BIOMOL. A monoclonal antibody of the same isotype but
reacting with human 2-macroglobulin (18) was used as a neg-
ative control. Antibodies and their sources were as follows:
anti-human Trx1 (Dr. Arne Holmgren), anti-His antibodies
(Qiagen), anti-GST and anti--actin (Sigma), anti-eEF1A1
(Abcam), and secondary antibodies and antibody specific for
ubiquitin (Dako).
Assays—Cell protein was determined (19) with bovine serum
albumin as a standard. Concentrations of purified recombinant
proteins were determined from A280. The thioredoxin activity
of Txnl1 was determined as described (20).
Reverse Transcription-PCR—For analyses of the Txnl1
expression, HeLa cells were treated with or without 0.1 mM
H2O2, 10mMDTT, or 10MMG132 for 4 h, beforemRNAwas
isolated using TRIzol (Invitrogen) and Turbo DNA-free
(Ambion). The RNA was reverse transcribed using Transcrip-
tor first strand cDNA synthesis (Roche Applied Science), puri-
fied usingGFXPCRDNA (GEHealthcare), and used for reverse
transcription-PCR. Actin was used as a negative control. The
primers specific for Txnl1 were as follows: forward, CCGTG-
GTCAAGTTCACCATGAG; reverse, GGTTCACTTCTT-
TCTGCCTCTTC.
Determination of Txnl1 Redox Potential—Txnl1 was purified
from HeLa cells on a MonoQ column (GE Healthcare) and a
column of Sephacryl S300 (GE Healthcare). Fractions were
assayed by dot blotting. Aliquots of 0.1 g of Txnl1 were incu-
bated in 100l of redox buffer in 100mMpotassiumphosphate,
pH 7.0, 1 mM EDTA, 10 mM redox buffer. Redox potentials of
buffers were calculated according to the Nernst equation, E 
E0  RT/nF  ln([GSSG]/[GSH]2) for glutathione buffers and
E E0RT/nF ln([LA]/[DHLA]) for buffers with lipoic acid
(LA)/dihydrolipoic acid (DHLA). E0 was taken to be0.240 V
for GSH/GSSG (21) and 0.290 V for DHLA/LA (22). Fully
reduced and oxidized Txnl1 were produced by substituting the
redox buffers by 25 mM DTT or 50 mM N,N,N,N-tetramethy-
lazodicarboxamide (diamide), respectively. After overnight
incubation at 4 °C in a helium atmosphere, the redox states of
Txnl1 were determined by a gel shift assay after modification
with 4-acetamido-4-maleimidylstilbene-2,2-disulfonic acid
(AMS) (23). Briefly, Txnl1 was precipitated by the addition of
250 l of 10% (w/v) trichloroacetic acid, and 40 l of 0.15%
deoxycholic acid. After 10 min, precipitates were collected by
centrifugation at 13,000 g for 5min andwashed in 3 1ml of
ice-cold acetone. Final pellets were dissolved into 20 l of 80
mM Tris/HCl, pH 6.8, 2% SDS, 25 mM AMS and incubated for
1 h at room temperature. Samples were separated by nonreduc-
ing SDS-PAGE and analyzed by immunoblotting.
Determination of the in Vivo Redox State—HeLa cells (1.4
106 cells/5-cm dish) were treated with or without 10 mM DTT
or 10mMdiamide for 5min at 37 °C.Themediumwas removed,
and the cells were washed rapidly with 20 mM N-ethylmaleim-
ide (NEM) in ice-cold PBS and incubated for 20minwith 20mM
NEM in PBS on ice. NEM was removed, and the cells were
scraped into 150 l of 80 mM Tris/HCl, pH 6.8, 0.2 mM phen-
ylmethylsulfonyl fluoride. After brief sonication, SDS was
added to 1%. Protein was reduced for 15 min at room temper-
ature with 10mMTris(2-carboxyethyl) phosphine, treated with
12 mM AMS at room temperature for 1 h and analyzed by non-
reducing SDS-PAGE and immunoblotting, using antibodies
specific for Txnl1.
Transfection—Interfering RNAs toward Txnl1 were pur-
chased from Qiagen, Txnl1-1 (SI00302064) and Txnl1-2
(SI03068394). Control small interfering RNAs (siRNAs) were
siCONTROL siRNA#1 RNA from Dharmacon. Attached and
exponentially growing MelJuSo cells were washed in PBS and
transfected with 10 nM siRNA using Lipofectamine RNAiMAX
(Invitrogen). The cultures were used 5 days after transfection.
Immunoprecipitation of 26 S Proteasomes for Mass Spec-
trometry—26 S proteasomes were isolated from HeLa cells by
immunoprecipitation and analyzed by two-dimensional gel
electrophoresis and mass spectrometry as described (13).
Txnl1-ProteasomeCo-precipitation—HeLa cells were homo-
genized by sonication in 4 volumes of buffer A. After centrifu-
gation (11,300  g, 30 min), aliquots of 250 ml of supernatant
were incubated with 20 l of Ni2-NTA-agarose beads (Qia-
gen) loaded with 5 g of purified His6-Txnl1 or, as a control,
His6-dihydroxyfolate reductase (DHFR). ForGST precipitation
experiments, purified GST-tagged Txnl1, truncations or GST
alone, was loaded on glutathione S-Sepharose (GE Healthcare)
beads and incubated with 3 g of purified 26 S proteasomes.
After incubation at 4 °C for 4 h with gentle agitation, the beads
were washed in 6  1 ml of buffer A. Bound proteins were
analyzed by SDS-PAGE and immunoblotting.
Differential Centrifugation—Differential centrifugation of
HeLa lysates was performed as described previously (13).
Txnl1 Stability—The stability of Txnl1 in HeLa cells was
assessed by following its degradation in cycloheximide-treated
cultures, essentially as described (13).
Txnl1 Substrate Capture—For capturing Txnl1 substrates in
vitro, His6-tagged Txnl1C34S, His6-tagged Txnl1C37S, or bovine
serum albumin (Sigma), were conjugated to CNBr-activated
Sepharose (GEHealthcare) to a concentration of about 4mg/ml
gel. HeLa cells (5 g) were harvested and lysed by sonication in
4 volumes of buffer B. The extracts were cleared by centrifuga-
tion (13,000  g, 30 min). The supernatant was tumbled at
room temperature for 2 hwith 40l of the Sepharose beads and
washed three times in buffer C, followed by three washes in
buffer D, before a final wash in buffer C. Bound proteins were
eluted for 30 min at room temperature with 10 mM DTT in
buffer C and resolved by SDS-PAGE before the proteins were
identified by mass spectrometry.
For detecting Txnl1 substrates in vivo, HEK293 cells were
stably transfected to express RGSHis6-taggedTxnl1C37S. About
3 g of these cells and mock-transfected control cells were
treatedwithNEMas described above and lysed by sonication in
4 volumes of buffer B. The extracts were cleared by centrifuga-
tion (13,000 g, 30min). The supernatantwas tumbledwith 40
l of Sepharose beads (GEHealthcare) containing immobilized
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anti-RGSHis6 antibodies (Qiagen) at 4 °C for 4 h. The beads
were washed three times in buffer B. Bound protein was
eluted by the addition of buffer D and centrifugation. The
supernatant was tumbled for 4 h at room temperature with
40 l of Ni2-NTA-agarose beads (Qiagen) and washed
extensively with buffer D and then
in buffer B. Protein was eluted in
SDS-PAGE sample buffer with
or without 2-mercaptoethanol.
The samples were separated by
SDS-PAGE and analyzed by
immunoblotting.
Protein Identification by Mass
Spectrometry—The protein was
identified using trypsin digestion, as
described previously (24). In short,
the relevant bands were excised
from the gel. The proteins were
reduced, alkylated using iodoacet-
amide, and digested by trypsin. The
resulting fragments were extracted,
purified using C18 ZipTip (Milli-
pore), and measured by matrix-as-
sisted laser desorption ionization
time-of-flight mass spectrometry
on an AutoFlex II instrument
equipped with TOF-TOF facility
(Bruker). Mass spectra of the tryptic
fragments were used for searching
against data bases. To confirm iden-
tifications, sequence information
was obtained for several fragments,
again by data base searching.
Pulse-Chase Experiments—Pulse-
chase experiments were performed
as described previously (25, 26).
Fluorescence Microscopy—The
localization of green fluorescent
protein-tagged Txnl1 was deter-
mined in HeLa cells transiently
transfected with pcDNA-DEST53-
Txnl1, as described (26).
RESULTS
Txnl1 Associates with 26 S Pro-
teasomes—26 S proteasomes from
HeLa cells were analyzed by two-
dimensional PAGE andmass spec-
trometry. Most known protea-
some subunits were detected (Fig.
1A), except Rpn3, Rpn5, Rpn7, and
Rpn12, which were not resolved,
perhaps because of poor solubility
of these proteins (13). We also
confirmed the proteasome associ-
ation of several known cofactors,
including PA28 (27), Hsp70 (28),
gankyrin (29), and Usp14/Ubp6
(28, 30). In addition to these proteins, Txnl1, a thioredoxin-
like protein implicated in endocytosis (31) and reactions to
glucose deprivation (32), was consistently found in the pro-
teasome preparations (Fig. 1A) but not in precipitations with
a control antibody (Fig. S1).
FIGURE1.Txnl1associateswith26Sproteasomes.A, proteasomeswereprecipitated fromHeLa cellswith an
antibody to subunit Rpn10 and analyzed by two-dimensional PAGE. Proteins were stained by Coomassie
Brilliant Blue and identifiedbymass spectrometry. Theheavy and light chain immunoglobulins of the antibody
used for precipitation are visible (Ig HC and Ig LC). Txnl1 (boldface type), which was identified with 49%
sequence coverage, is a novel proteasome component. B, 26 S proteasomes from HeLa cell extracts (lane 1)
were precipitated using His6-tagged Txnl1 (lane 2) or His6-tagged DHFR as a control (lane 3). The precipitated
material was separated by SDS-PAGE and immunoblotting. Proteasomes were detected with an antibody to
subunit Rpt1. C, purified His6-tagged Txnl1 (lane 1) was added in excess to HeLa cell extracts before precipita-
tion (IP) with an antibody to the subunit Rpn10 (lane 2) or with a nonspecific control antibody of the same
isotype (lane 3). Precipitated material was separated by SDS-PAGE and immunoblotted (IB) using an antibody
to theHis6 tag.D, domain organizationof full-length Txnl1 and theN- andC-terminal truncations utilized in the
binding studies. The N terminus of Txnl1 contains a TRX domain (green), whereas the C-terminal part contains
a DUF1000 domain (red). The black bar indicates the length of 100 amino acids. E, purified 26 S proteasomes
(lane 1)wereprecipitatedwith the indicatedGST fusionproteins. As a control, GST alonewasused. Precipitated
materialwas separatedbySDS-PAGEand immunoblottedusinganantibody to the subunit Rpt5. Equal loading
was checked by Ponceau S staining.
Txnl1 Is a Novel Proteasome Component
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The position of Txnl1 in two-dimensional gels corresponded
with its predicted molecular mass of 32.2 kDa and isoelectric
point of 4.8. Previous studies have shown that 26 S proteasomes
are able to remodel scrambled RNase A (33), which could indi-
cate that proteasomes were associated with a thioredoxin func-
tion.We sought to confirm the association of proteasomes and
Txnl1 using a different approach. His6-tagged Txnl1 and, as a
control, His6-DHFR were bound to Ni2-NTA-agarose beads.
When incubated with HeLa lysates, His6-Txnl1 precipitated 26
S proteasomes, whereas His6-DHFR did not (Fig. 1B). Con-
versely, if 26 S proteasomes were precipitated with antibodies
to Rpn10, added His6-Txnl1 was co-precipitated (Fig. 1C).
Some cofactors, including Rad23, associate with protea-
somes in an ATP-dependent manner (28). We found that the
Txnl1-proteasome interaction was independent of ATP (Fig.
S1). However, binding was salt-sensitive, since it was totally
abrogated in buffers containing 500 mM NaCl (Fig. S1). The
interaction between Txnl1 and the 26 S proteasome was not
sensitive to the redox potential of the buffer (Fig. S2).
Txnl1 has an N-terminal thioredoxin (TRX) domain and a
C-terminal domain of unknown function 1000 (DUF1000) (Fig.
1D). Precipitation experiments showed (Fig. 1E) that the
DUF1000 domain of Txnl1 was necessary and sufficient to
mediate the interaction with the 26 S proteasome.
Txnl1 Is a Component of the 19 S Regulatory Complex—The
26 S proteasome is composed of two stable subparticles, the 20
S cylinder and the 19 S regulatory complex. Nondenaturing
electrophoresis and immunoblotting of HeLa cell lysates con-
firmed (34) that HeLa cells contain a significant fraction of free
20 S proteasomes (Fig. 2A). Txnl1 co-migrated with 26 S pro-
teasomes but not with 20 S proteasomes (Fig. 2A), indicating
that Txnl1 associates with a component of the 19 S regulatory
complex. The smear of Txnl1, seen below the band correspond-
ing to 26 S proteasomes, is probably caused by continuous
release of Txnl1 from 26 S proteasomes during electrophoresis.
This is consistent with the lability of the interaction between
Txnl1 and 26 S proteasomes. His6-tagged and wild type Txnl1
have pI values of 5.3 and 4.8, respectively, and should therefore
migrate at almost the same rate in nondenaturing electrophore-
sis (pH 8.3). Free His6-tagged Txnl1 migrated much faster than
the 26 S proteasome (Fig. 2A), and no free Txnl1 was observed
in the lysate. Therefore, most or all of the Txnl1 must initially
have been associated with proteasomes.
Txnl1 Is a Nearly Stoichiometric Component of the 26 S
Proteasome—In accordancewith the results from the nondena-
turing electrophoresis (above), at least 85% of the Txnl1 in
HeLa cell extracts was co-precipitated with 26 S proteasomes,
as determined by quantitative immunoblotting (Fig. S3). We
cannot ascertain if the remaining 15% of the total cellular Txnl1
was released from proteasomes during the experiment or if it is
found in the free form also in the intact cells.
The amounts of the 26 S proteasome subunit Rpt5 andTxnl1
in HeLa cells were determined by quantitative immunoblotting
of dilution series of total cell protein and His6-tagged Rpt5 and
Txnl1 as standards. The cells were dissolved in 2% SDS to allow
determination of the protein concentration before the buffer
was reconstituted to normal SDS sample buffer. Care was taken
to use data only from regions where the curves, describing the
correlation between color development and dilution of the cell
extracts, were parallel with the standard curves (data not
shown). The results revealed that HeLa cells contain around
220g of Txnl1 and 230g of Rpt5/g of cell protein. Txnl1 and
Rpt5 are therefore abundant proteins present in roughly
equimolar amounts.
Txnl1 Binds Directly to Rpn11—Todetermine direct interac-
tions between Txnl1 and proteasome subunits, GST and GST-
tagged Txnl1 were incubated with several His6-tagged subunits
of the 19 S regulatory complex expressed inEscherichia coli and
then precipitated. Only subunit Rpn11 bound to Txnl1 (Fig.
2B). Structurally, Rpn11 somewhat resembles the Csn5 subunit
of the COP9 signalosome. However, we did not observe any
interaction between Txnl1 and Csn5 (Fig. 2C).
Txnl1 Is a Stable Protein—The stability of Txnl1 was ana-
lyzed by immunoblotting of HeLa cells, treated with cyclohex-
imide to stop protein synthesis. The level of Txnl1 did not sig-
nificantly decrease after 8 h (Fig. S4), indicating that Txnl1 is a
relatively stable protein.
Txnl1 Expression—Like most other proteasome compo-
nents, Txnl1 was expressed at roughly similar levels in all tested
tissues (Fig. 3A).
Components of the ubiquitin-proteasome system are
up-regulated at the mRNA level in response to proteasome
inhibition (35, 36).
Neither oxidative nor reductive stress significantly altered
the Txnl1 mRNA level as determined by reverse transcription-
PCR. However, proteasome inhibition significantly induced
Txnl1 mRNA (Fig. S5).
Txnl1 Is a Soluble Cytoplasmic and Nuclear Protein—26 S
proteasomes and other components of the ubiquitin system are
mostly soluble proteins localized in the cytoplasm and nucleus
(37). Similarly, upon centrifugation of HeLa cell extracts, Txnl1
was found only in the supernatant (Fig. 3B).
FIGURE 2. Txnl1 is associated with the 19 S regulatory complex. A, HeLa
cell extracts were separated by nondenaturing PAGE and analyzed by immu-
noblotting (IB) using antibodies against a 20 S subunit (4), a 19 S subunit
(Rpn2), and Txnl1. As a control, a purified sample of His6-Txnl1 was also sub-
jected to nondenaturing PAGE and Coomassie-stained. His6-tagged Rpn11
(B) or His6-tagged Csn5 (C) (lane 1) was precipitated with glutathione-Sepha-
rosebeads loadedwithGST (lane 2) andGST-Txnl1 (lane 3). Precipitatedmate-
rial was separated by SDS-PAGE and analyzed by immunoblotting with an
antibody to the His6 tag.
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Another thioredoxin, Trx1, is secreted via an endoplasmic
reticulum-Golgi-independent pathway (38). However,
although we could confirm the secretion of Trx1 into the
growth medium, Txnl1, like the proteasome, was exclusively
present in the interior of HeLa cells (Fig. 3C).
Our antibodies were not suitable for immunolocalization
studies, but green fluorescent protein-tagged Txnl1 was pres-
ent in HeLa cells throughout the cytoplasm and nucleus (Fig.
3D). The homologous Trx1 translocates to the nucleus in
response to protein kinase C stimulation (39). However, no
change in the subcellular localization of Txnl1 was observed in
the presence of 12-O-tetradecanoylphorbol-13-acetate and
bisindolylmaleimide (data not shown).
Txnl1 Displays Thioredoxin Activity—Txnl1 contains a thi-
oredoxin domain, which is 41% identical to that of humanTrx1.
Both the active site CGPC motif and the proline loop are iden-
tical (Fig. 4A). With insulin as substrate (20), the specific activ-
ity of Txnl1 was about 30% of that of E. coli thioredoxin (Fig.
4B). The activity was completely lost when the first active site
cysteine was altered to a serine (C34S) (Fig. 4B).
Redox Properties of Txnl1—The redox potential of Txnl1 and
the redox state of Txnl1 in the cell might provide us with clues
about the function of Txnl1 in vivo. Purified Txnl1 from HeLa
cells was incubatedwith redox buffers and then allowed to react
with the thiol-specific reagent AMS, which adds 450 Da for
each free cysteine in the protein (23). AMS-modified
(reduced) and unmodified (oxidized) Txnl1 were separated by
SDS-PAGE and detected by immunoblotting. Curiously, even
withDTT,wewere never able to completely reduce the purified
Txnl1 (Fig. 5A), indicating that during purification, a fraction of
Txnl1 underwent irreversible oxidation. This fraction was
ignored in the following calculation. To get a rough estimate of
the Txnl1 redox potential, the ratios of reduced to oxidized
Txnl1 were plotted against the E0 of the buffers (Fig. 5B). The
curve follows the Nernst equation and shows that Txnl1 has a
redox potential of about250 mV, comparable with the redox
potential of270 mV for thioredoxin (40).
Next, we wanted to establish the redox state of Txnl1 in vivo.
To prevent active site cysteines from engaging in thiol-disulfide
exchange reactions during or after cell lysis, HeLa cells were
incubated with the cell-permeable alkylating agent NEM. Sub-
sequently, lysates were treated with DTT under denaturing
conditions to reduce disulfide bonds (23). The resulting cys-
teines were then detected by AMS treatment and SDS-PAGE,
followed by immunoblotting, as before. Control samples were
generated by incubating cells under reducing conditions, using
10 mM DTT, or under oxidizing conditions with 10 mM dia-
mide, prior to treatment withNEM. Txnl1 was found to be fully
reduced in untreated HeLa cells (Fig. 5C).
eEF1A1 Is a Substrate for Txnl1 in Vivo—As part of the cat-
alytic mechanism, reduced thioredoxin and oxidized target
proteins formmixed disulfide intermediates. Subsequently, thi-
oredoxin itself forms an intramolecular disulfide bridge, releas-
ing the reduced target. The intermediatemixeddisulfide state is
stabilizedwhen the thioredoxin lacks the second cysteine in the
active site CXXCmotif. Suchmutant thioredoxin can therefore
trap prospective substrates (41, 42), whichwill be released upon
reduction of the disulfide bond (Fig. 6A).
Txnl1 active site point mutant proteins were covalently cou-
pled to Sepharose beads and incubated with HeLa cell lysates.
After incubation, the beads were washed extensively in a buffer
containing 8 M urea to ensure that only covalently bound pro-
teins were isolated. Then the bound substrates were released
with DTT and resolved by SDS-PAGE. Mass spectrometry of
the excised bands identified the proteins, as indicated (Fig. 6B).
With the Txnl1C34S and Txnl1C37S mutant thioredoxins, a pat-
tern of four or five bands was visible on the gel. In a control
experiment with bovine serum albumin coupled to Sepharose
beads, only bovine serum albumin was released from the resin
(Fig. 6B). Although thioredoxins preferably form mixed disul-
fides with the first cysteine of the active site CXXCmotif, some
may utilize either cysteine for the initial reaction at the active
site (43). All of the isolated proteinsmay therefore be substrates
of Txnl1. Nonetheless, of the isolated proteins, eEF1A1 was
mainly associated with the Txnl1C37S mutant (Fig. 6B). To ana-
lyze if eEF1A1 is also associated with a Txnl1C37S mutant in
vivo, HEK293 cells were stably transfected to express RGSHis6-
tagged Txnl1C37S. The cells were treated with NEM to block
free cysteines before cell lysis. Then the RGSHis6-Txnl1C37S
was isolated by first a native immunoprecipitation using anti-
RGSHis6 antibodies. The precipitate was dissolved in 8 M urea,
and theRGSHis6-taggedTxnl1was again precipitated, this time
with Ni2-NTA-agarose beads. Immunoblotting showed that
the Txnl1C37S formed mixed disulfides with various cell pro-
teins in vivo (Fig. 6C, left), which disappeared when -mercap-
toethanol was added to the sample prior to electrophoresis.
FIGURE 3. Txnl1 is a widely expressed cytoplasmic and nuclear protein.
A, mouse tissueswere analyzedby SDS-PAGE andblotting (IB) with anti-Txnl1
antibodies. Txnl1 was found in all tested tissues at about equal abundance.
B, a HeLa cell homogenatewas separatedby centrifugation into pellet (P) and
supernatant (S). The pellet was then resuspended in the same volume as the
supernatant before analysis of the fractions by SDS-PAGE and blotting using
antibodies specific for Txnl1.C, samplesof spentHeLamedia (extracellular (E))
andHeLa cells (intracellular (I)) were separated by SDS-PAGE and analyzed by
blotting with antibodies specific for thioredoxin (anti-Trx1), the proteasome
(anti-Rpn2), andTxnl1 (anti-Txnl1).D, confocalmicrographsofHeLa cells tran-
siently transfected to express green fluorescent protein-taggedTxnl1 (green).
The cells were stained with phalloidin (red) and 4,6-diamidino-2-phenylin-
dole (DAPI) (blue) to detect actin and the nucleus, respectively.
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Release of eEF1A1 from Txnl1C37S in the presence of reducing
agent could also be shown by immunoblotting (Fig. 6C, right),
confirming that eEF1A1 is a substrate for Txnl1 also in vivo.
Effect of Knockdown of Txnl1 Expression—eEF1A1 plays a
role in protein degradation (14) by targeting misfolded nascent
proteins to the 26 S proteasome in collaboration with Rad23 (5,
15). Proteolysis might therefore be impaired in cells with a
decreased content of Txnl1. To check this prediction, Txnl1
expression in MelJuSo cells was knocked down with siRNA
(Fig. 7). The amounts of Rpn2, a subunit of the regulatory com-
plex of 26 S proteasomes, and of Trx1 (Fig. 7) were the same as
in the control cultures. Thus, cells do not compensate for the
lack of Txnl1 by inducing proteasomes or Trx1.
In order to test if protein degradation was affected, we per-
formed pulse-chase analyses on cells transfected with Txnl1-
specific siRNA or with control siRNA. However, no significant
changes were observed in the degradation of bulk protein (Fig.
S6). The degradation kinetics of model proteasome substrates
of the secretory pathway, CD3-yel-
low fluorescent protein and 1-an-
titrypsin (25), were also not signifi-
cantly affected byTxnl1 knockdown
(Figs. S7 and S8), indicating that
Txnl1 is important only for the deg-
radation of a subset of cell proteins.
However, in response to Txnl1
knockdown, we did observe a mod-
erate increase in the amount of
ubiquitin-protein conjugates (Fig.
7), revealing that the ubiquitin-pro-
teasome system is indeed compro-
mised in cells lacking Txnl1.
DISCUSSION
Txnl1 (thioredoxin-like protein
1) (44), also known as TRP32 (thi-
oredoxin-related protein of 32 kDa)
(45), is a relatively uncharacterized
but widely expressed thioredoxin
(44, 45).We confirmed that Txnl1 is
soluble and present in the nucleus
and cytoplasm (45), a localization
that it shares with Trx1. However,
unlike Trx1 (38, 39), Txnl1 is not
secreted from cells, and its subcellu-
lar localization is not regulated by
protein kinase C activity.
Previous studies have revealed
that Txnl1 is involved in endocyto-
sis (31) and in protection against
glucose deprivation-induced cyto-
toxicity (32). Such effects are prob-
ably indirect for a proteasome
component.
In C. elegans, Txnl1 expression is
up-regulated by the unfolded pro-
tein response (46). We did not
observe any change in the Txnl1
mRNA level when unfolded protein response was induced with
DTT. However, as shown by both Lundgren et al. (47) and us,
Txnl1 is induced by inhibition of proteasomes, like other com-
ponents of the ubiquitin-proteasome system (35, 36). Previous
studies have shown that 26 S proteasomes are able to remodel
scrambled RNase A (33), which could indicate that protea-
somes were associated with a thioredoxin function.
Txnl1 has thioredoxin activity (45). We found that Txnl1
displays a specific activity of about 30% of that of E. coli thiore-
doxin and has a reduction potential of about250mV. InHeLa
cells, Txnl1 is present almost exclusively in a reduced form, like
thioredoxin.
Txnl1 is an abundant protein, present in amounts roughly
equimolar with subunits of the 26 S proteasome. At least 85% of
cellular Txnl1 is proteasome-associated, indicating that Txnl1
must be closely tied to proteolysis. Since Txnl1 associated with
preexisting 26 S proteasomes, it may be better defined as a
proteasome-interacting protein, rather than an actual subunit.
FIGURE 4.Txnl1 is an active thioredoxin.A, Txnl1 and Trx1were alignedusing T-Coffee version 1.41. Identical
and homologous residues have been shaded. The active site CGPC motif is shown in red, and the conserved
proline is shown in green. B, specific activities of Txnl1, the Txnl1C34S mutant, and a sample of Txnl1 that had
been boiled were determined. The E. coli thioredoxin (Trx) was included for comparison. ***, p 0.01 (t test).
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We show that Txnl1 specifically utilizes the DUF1000
domain to associate with the 26 S proteasome. We therefore
suggest that the DUF1000 domain be instead named the pro-
teasome-interacting thioredoxin (PITH) domain. The only
other human protein that contains a PITH domain is
C1ORF128, which is uncharacterized and does not contain any
other known protein domains but has recently been found to
associate with 26 S proteasomes (48). It therefore appears that
the PITH domain is a general proteasome-interacting module.
Due to its associationwith the proteasome, onewould expect
Txnl1 knockdown to result in impaired intracellular protein
degradation. Many proteins in the endoplasmic reticulum are
stabilized by disulfide bonds. However, in response to Txnl1
siRNA, we did not observe any significant change in the degra-
dation of bulk protein or model substrates of the endoplasmic
reticulum-associated degradation pathway.
Recently, the Txnl1 orthologue in fission yeast, Txl1, was
characterized. The null mutant did not display any specific
responses upon glucose deprivation but was moderately sensi-
tive to alkyl hydroperoxide (49). However, under normal
growth conditions, the mutant did not exhibit any obvious
phenotypes (49), corroborating the modest phenotype we
found upon knockdown of Txnl1 in mammalian tissue cul-
ture cells. Curiously, the budding yeast genome does not
encode a Txnl1 orthologue, so perhaps the other cytoplasmic
thioredoxins, Trx1 and Trx2, maintain Txnl1 function in
this organism. Accordingly, by proteomics, both Trx1 and
Trx2 were recently found to associate with 26 S proteasomes
in budding yeast (50).
FIGURE 5. Redox properties of Txnl1. A, purified Txnl1 was incubated with
glutathione and dihydrolipoate redox buffers, as indicated, or with the oxi-
dizing agent diamide or the reducing agent DTT. Reduced cysteine residues
were then modified with AMS, and the proteins were resolved by SDS-PAGE
andblotting (IB) using antibodies specific for Txnl1.B, the fractionsof reduced
Txnl1, determined from A, were plotted versus the redox potentials of the
buffers. At about 250 mV, half of Txnl1 was reduced. C, HeLa cells were
preincubated with NEM and lysed. The extracts were reduced with DTT and
treatedwith AMS before being resolved by SDS-PAGE and immunoblot anal-
ysis. Lysates from cells pretreated with DTT or diamide were used as markers
for the completely reduced and oxidized protein, respectively.
FIGURE 6. Isolation of eEF1A1 as a Txnl1 substrate. A, potential substrates
for Txnl1 were isolated. Single pointmutants in the active site CXXCmotif are
prone to formadisulfidebondwith the substrate,which can subsequently be
elutedby reductionof thedisulfidebondwithDTT. Thebeadswerewashed in
urea to ensure that only covalently bound proteins were isolated. B, the iso-
lated proteins were resolved by SDS-PAGE and stained with Coomassie. Pro-
teins were identified by mass spectrometry as indicated. C, HEK293 cells
mock-transfected or transfected to express RGSHis6-tagged Txnl1
C37S were
used in denaturing precipitation experiments to isolate in vivo Txnl1 sub-
strates. Left, in the absence of reducing agent, Txnl1 formed a slowmigrating
smear, probably due to formation of mixed disulfides with various cellular
substrates. Right, in the presence of reducing agent eEF1A1 was released. *,
an unknown contaminant. IB, immunoblot.
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Potential substrates for a proteasome-associated thioredoxin
encompass the proteasome itself, proteasome substrates, and
proteasome cofactors. Oxidation and glutathionylation itself
may affect proteasome activity (51, 52). Previous studies have
shown that proteasomes are prone to oxidation (53). Especially,
subunit Rpt3 (51) and the subunits Rpt3 (54) and Rpn12 (55)
have been shown to be targets of thioredoxin.
The experiments with active sitemutated Txnl1 showed that
- and -tubulin, Hsp70, and eEF1A1 formed mixed disulfides
with cysteine in the active site. With basically the same tech-
nique, Wiseman et al. (56) were unable to capture such
covalently bound substrates, perhaps because of an unfavorable
ratio of cell extract to mutant Txnl1 or other experimental
details.
Certainly - and -tubulin are subject to oxidative modifica-
tion and are targeted by thioredoxins (57). Hsp70-type chaper-
ones are also prone to oxidative inactivation andmay be subject
to redox regulation (58). However, for these substrates, it is
presently not clear why a proteasome-associated thioredoxin
such as Txnl1 should target these proteins. Most thioredoxins
possess very broad substrate specificities. It is therefore not
unexpected that Txnl1 can also have several substrates.
eEF1A1 seems to be a substrate for Txnl1 both in vitro and in
vivo and can easily be placed in a physiological context. Besides
of its well described function in recruiting codon-specific ami-
noacyl-tRNAs to the ribosome, eEF1A1 also possesses chaper-
one-like activity (59, 60) and functions in targeting of newly
synthesized, damaged proteins to the proteasome (5, 14, 15),
perhaps through its binding to subunits Rpn2 and Rpt4 (61).
Previously, eEF1A1 was shown to be prone to oxidative modi-
fication and to be a substrate for the Dictyostelium discoideum
thioredoxin Ddtrx1 (62). Perhaps during oxidative stress, when
nascent protein folding is challenged, Txnl1 functions to ensure
that co-translationally damaged proteins are efficiently
degraded by protecting eEF1A from oxidative inactivation.
In conclusion, the results presented here agree with and
complement those obtained by Wiseman et al. (56). We show
that Txnl1 is a novel redox active and nearly stoichiometric
component of the 26 S proteasome, which interacts with the 26
S proteasome via its C-terminal PITH domain. Thus, Txnl1
equips 26 S proteasomes with a hitherto unrecognized enzy-
matic function, namely protein disulfide reduction. However,
despite our efforts, the exact molecular mechanism for Txnl1
function remains elusive. Hopefully, future studies can utilize
the data presented here for more in depth analyses of Txnl1
function.
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